Immunocore Holdings plc
immunocore.com
Actively hiring
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Immunocore Completes Enrollment in Phase 3 Melanoma Trial
Detailed price information for Immunocore Holdings Plc ADR (IMCR-Q) from The Globe and Mail including charting and trades.
Read more
Report
Immunocore Holdings plc (IMCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Read more
Report
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK (tebentafusp) in previously treated advanced melanoma
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK (tebentafusp) in previously treated…...
Read more
Report
Immunocore to present at upcoming investor conferences
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 1 September…...
Read more
Report
Immunocore reports second quarter financial results and provides a business update
Immunocore reports second quarter financial results and provides a business update KIMMTRAK (tebentafusp-tebn) net revenues of $115.9 million in…...
Read more
Report
Immunocore to report second quarter 2026 financial results and host call on August 6, 2026
Immunocore to report second quarter 2026 financial results and host call on August 6, 2026 (OXFORDSHIRE, England & RADNOR, PA &…...
Read more
Report
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Brenetafusp monotherapy resulted in…...
Read more
Report
Immunocore reports first quarter financial results and provides a business update
Immunocore reports first quarter financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q1 net sales of $106.7…...
Read more
Report
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A02:01+ patients with metastatic uveal melanoma
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A02:01+ patients with metastatic uveal melanoma OS benefit…...
Read more
Report
Show more news
People
Brian Di Donato
Executive Officer
David Berman
Executive Officer
Tina St. Leger
Executive Officer
Bahija Jallal
Executive Officer, Director
John Bell
Director
Robert Perez
Director
Peter Ratcliffe
Director
Siddharth Kaul
Director
Roy Herbst
Director
Kristine Peterson
Director
Travis Coy
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Abingdon
United Kingdom
Regional office
200-500 est. staff
Immunocore Limited 92 Park Drive, Abingdon, Oxon, OX14 4RY, UK
Financials
Total raised
$140M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2022 | $140M | Details |